{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-134812","form_type":"8-K","ticker":null,"cik":"0001962918","company_name":"ACELYRIN, Inc.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.323026+00:00","generated_at":"2026-06-02T07:18:20.054252+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"ACELYRIN appoints Mina Kim as CEO; founder Lin steps down; cash $678.5M","bullets":["Mina Kim appointed CEO and board member effective May 9; Shao-Lee Lin steps down as CEO and from board.","Cash, cash equivalents and short-term marketable securities total $678.5M at March 31, 2024; funding into 2026 reiterated.","Izokibep Phase 3 HS trial enrollment completed (258 patients); top-line data expected Q3 2024.","Positive proof-of-concept for lonigutamab in thyroid eye disease; Phase 2b/3 trial planned H2 2024.","Company will not host Q1 2024 earnings call; 10-Q to be filed by May 14, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-134812","json":"https://secwatch.observer/filing/0001193125-24-134812.json","markdown":"https://secwatch.observer/filing/0001193125-24-134812.md","text":"https://secwatch.observer/filing/0001193125-24-134812.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1962918/000119312524134812/0001193125-24-134812-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1962918/000119312524134812/d799182d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T07:18:20.054252+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"17bd162c93","claim":"Ron Oyston departed as Chief People Officer at ACELYRIN, Inc..","evidence_excerpt":"Effective on May 8, 2024, the Company and Ron Oyston mutually agreed that Mr. Oyston will step down from his position as Chief People Officer, effective August 15, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1962918/000119312524134812/0001193125-24-134812-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"stepped down"},{"label":"Role","value":"Chief People Officer"}],"fact_type":"executive_change"},{"claim_id":"c1a5e7a9ef","claim":"Mina Kim was appointed as Chief Executive Officer at ACELYRIN, Inc..","evidence_excerpt":"Effective May 9, 2024, Mina Kim was appointed as the Chief Executive Officer of the Company and was appointed as a member of the Board of Directors of the Company (the “Board”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1962918/000119312524134812/0001193125-24-134812-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"cba610411e","claim":"Shao-Lee Lin departed as Chief Executive Officer at ACELYRIN, Inc..","evidence_excerpt":"By mutual agreement of Shao-Lee Lin, M.D., Ph.D. and the Company, Dr. Lin stepped down from her position as Chief Executive Officer and as a member of the Board, effective on May 8, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1962918/000119312524134812/0001193125-24-134812-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"stepped down"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}